{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:27:02Z","timestamp":1753892822701,"version":"3.41.2"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bipolar disorder is an often recurrent mood disorder that is associated with a significant economic and health-related burden. Increasing the availability of health-economic evidence may aid in reducing this burden. The aim of this study is to describe the design of an open-source health-economic Markov model for assessing the cost-effectiveness of interventions in the treatment of Bipolar Disorders type I and II, TiBipoMod.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TiBipoMod is a decision-analytic Markov model that allows for user-defined incorporation of both pharmacological and non-pharmacological interventions for the treatment of BD. TiBipoMod includes the health states remission, depression, (hypo)mania and death. Costs and effects are modeled over a lifetime horizon from a societal and healthcare perspective, and results are presented as the total costs, Quality-Adjusted Life Years (QALY), Life Years (LY), and incremental costs per QALYs and LYs gained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Functionalities of TiBipoMod are demonstrated by performing a cost-utility analysis of mindfulness-based cognitive therapy (MBCT) compared to the standard of care. Treatment with MBCT resulted in an increase of 0.18 QALYs per patient, and a dominant incremental cost-effectiveness ratio per QALY gained for MBCT at a probability of being cost-effective of 71% when assuming a \u20ac50,000 willingness-to-pay threshold.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TiBipoMod can easily be adapted and used to determine the cost-effectiveness of interventions in the treatment in Bipolar Disorder type I and II, and is freely available for academic purposes upon request at the authors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1030989","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:29:21Z","timestamp":1668061761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Designing and testing of a health-economic Markov model to assess the cost-effectiveness of treatments for Bipolar disorder: TiBipoMod"],"prefix":"10.3389","volume":"13","author":[{"given":"Anne","family":"Kleijburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joran","family":"Lokkerbol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline J.","family":"Regeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"journal-title":"Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5).","year":"2013","key":"B1","doi-asserted-by":"publisher","DOI":"10.1176\/APPI.BOOKS.9780890425596"},{"key":"B2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/ARCHGENPSYCHIATRY.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2\/JQUERY.MIN.JS","author":"Kupka","year":"2015","journal-title":"Multidisciplinary Guidelines on Bipolar Disorder - Netherlands."},{"key":"B4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40273-016-0473-1","article-title":"A systematic review and critical appraisal of economic evaluations of pharmacological interventions for people with bipolar disorder.","volume":"35","author":"Mavranezouli","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/J.JAD.2020.06.064","article-title":"Economic evaluations of non-pharmacological interventions and cost-of-illness studies in bipolar disorder: a systematic review.","volume":"276","author":"Kraiss","year":"2020","journal-title":"J Affect Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3310\/HTA11390","article-title":"A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.","volume":"11","author":"Soares-Weiser","year":"2007","journal-title":"Health Technol Assess."},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.JAD.2017.09.011","article-title":"The economic burden of bipolar I disorder in the United States in 2015.","volume":"226","author":"Cloutier","year":"2018","journal-title":"J Affect Disord."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/NRDP.2018.8","article-title":"Bipolar disorders.","volume":"4","author":"Vieta","year":"2018","journal-title":"Nat Rev Dis Prim."},{"key":"B9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/J.1600-0447.2004.00403.X","article-title":"The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.","volume":"110","author":"Hakkaart-van Roijen","year":"2004","journal-title":"Acta Psychiatr Scand."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/S12991-018-0178-2","article-title":"A survey of caregiver burden in those providing informal care for patients with schizophrenia or bipolar disorder with agitation: results from a European study.","volume":"17","author":"Blanthorn-Hazell","year":"2018","journal-title":"Ann Gen Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/J.1399-5618.2007.00365.X","article-title":"Prevalence and correlates of burden among caregivers of patients with bipolar disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder.","volume":"9","author":"Perlick","year":"2007","journal-title":"Bipolar Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0165-0327(14)70003-5","article-title":"The prevalence and burden of bipolar depression.","volume":"169","author":"Miller","year":"2014","journal-title":"J Affect Disord."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2015.00164\/BIBTEX","article-title":"Economic evaluation enhances public health decision making.","volume":"3","author":"Rabarison","year":"2015","journal-title":"Front Public Health."},{"journal-title":"Methods for Health Economic Evaluations-A Guideline based on Current Practices in Europe.","year":"2015","key":"B14"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","author":"Briggs","year":"2006","journal-title":"Decision Modelling for Health Economic Evaluation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14737167.2019.1632194","article-title":"Designing and testing of a health-economic markov model for prevention and treatment of early psychosis.","volume":"20","author":"Wijnen","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14737167.2021.1844566","article-title":"Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder.","volume":"21","author":"Lokkerbol","year":"2021","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2.","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Making."},{"journal-title":"Guidelines for Health Economic Evaluations in The Netherlands.","year":"2016","key":"B19"},{"key":"B20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/0272989X08315241","article-title":"The half-cycle correction explained: two alternative pedagogical approaches.","volume":"28","author":"Naimark","year":"2008","journal-title":"Med Decis Making."},{"journal-title":"WHO\u2013Choosing Interventions that are Cost Effective (WHO\u2013CHOICE). Threshold Values for Intervention Cost-Effectiveness by Region.","year":"2010","key":"B21"},{"journal-title":"Disease Burden in practice.","year":"2018","author":"Vijgen","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/BDI.12423","article-title":"The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013.","volume":"18","author":"Ferrari","year":"2016","journal-title":"Bipolar Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1192\/BJP.187.6.559","article-title":"Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.","volume":"187","author":"Chisholm","year":"2005","journal-title":"Br J Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/J.CLINTHERA.2009.06.009","article-title":"Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a markov model analysis.","volume":"31","author":"Fajutrao","year":"2009","journal-title":"Clin Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.18553\/jmcp.2006.12.4.322","article-title":"The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.","volume":"12","author":"Calvert","year":"2006","journal-title":"J Manag Care Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/0269881106068395","article-title":"Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.","volume":"21","author":"McKendrick","year":"2007","journal-title":"J Psychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696990903266612","article-title":"Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar i disorder.","volume":"12","author":"Woodward","year":"2009","journal-title":"J Med Econ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/11538350-000000000-00000","article-title":"Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar i disorder.","volume":"28","author":"Woodward","year":"2010","journal-title":"Pharmacoeconomics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/ARCHPSYC.58.9.844","article-title":"Excess mortality in bipolar and unipolar disorder in Sweden.","volume":"58","author":"\u00d6sby","year":"2001","journal-title":"Arch Gen Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/J.SCHRES.2011.06.008","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder.","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1192\/BJP.BP.117.202606","article-title":"Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014.","volume":"211","author":"Hayes","year":"2017","journal-title":"Br J Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/11594930-000000000-00000","article-title":"Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.","volume":"30","author":"Ekman","year":"2012","journal-title":"PharmacoEconomics."},{"key":"B34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/J.EURPSY.2008.07.006","article-title":"The primacy of mania: a reconsideration of mood disorders.","volume":"24","author":"Koukopoulos","year":"2009","journal-title":"Eur Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/J.JAD.2013.05.059","article-title":"Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias.","volume":"151","author":"Koukopoulos","year":"2013","journal-title":"J Affect Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/J.1399-5618.2007.00467.X","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/ARCHPSYC.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder.","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/ARCHPSYC.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.","volume":"60","author":"Judd","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S1461145703003341","article-title":"Long-term symptomatic status of bipolar I vs. bipolar II disorders.","volume":"6","author":"Judd","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/J.1399-5618.2003.00091.X","article-title":"A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders.","volume":"6","author":"Joffe","year":"2004","journal-title":"Bipolar Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/archgenpsychiatry.2010.15","article-title":"Longitudinal course of bipolar I disorder duration of mood episodes.","volume":"67","author":"Solomon","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.euroneuro.2015.07.013","article-title":"Recurrence rates in bipolar disorder : systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials.","volume":"25","author":"V\u00e1zquez","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"journal-title":"R: A Language and Environment for Statistical Computing.","year":"2020","key":"B43"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2012-002373","article-title":"Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden.","volume":"3","author":"Westman","year":"2013","journal-title":"BMJ Open."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA55080403","article-title":"Suicide risk in bipolar disorder: a brief review.","volume":"55","author":"Dome","year":"2019","journal-title":"Medicina."},{"journal-title":"Bipolar Disorder: Assessment And Management - Clinical Guideline.","year":"2014","key":"B46"},{"key":"B47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology.","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/S40345-018-0130-Z","article-title":"A nationwide study on concordance with multimodal treatment guidelines in bipolar disorder.","volume":"6","author":"Renes","year":"2018","journal-title":"Int J Bipolar Disord."},{"journal-title":"Guidelines on Renal Toxicity With Chronic Lithium Use [Dutch Report]","year":"2013","author":"de Beus","key":"B49"},{"key":"B50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations.","volume":"29","author":"Van Baal","year":"2011","journal-title":"Pharmacoeconomics."},{"journal-title":"Costing Manual: Methodology for Costing Research and Reference Prices in Health Economic Evaluations [Dutch Report]","year":"2015","author":"Hakkaart-van Roijen","key":"B51"},{"key":"B52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jad.2005.03.017","article-title":"Patient-based utilities for bipolar disorder-related health states.","volume":"87","author":"Revicki","year":"2005","journal-title":"J Affect Disord."},{"key":"B53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/S40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users.","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/S40273-019-00844-Y\/TABLES\/4","article-title":"TECH-VER: a verification checklist to reduce errors in models and improve their credibility.","volume":"37","author":"B\u00fcy\u00fckkaramikli","year":"2019","journal-title":"Pharmacoeconomics."},{"key":"B55","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/A.12033","article-title":"A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder.","volume":"127","author":"Perich","year":"2013","journal-title":"Acta Psychiatr Scand."},{"journal-title":"Bipolar Disorder | Treatment Options for Psychiological and Psychosocial Therapy - Roadmap to Dutch Treatment Guidelines.","year":"2017","key":"B56"},{"journal-title":"Budget Impact Analysis - Bipolar Disorder treatment guidelines [Dutch report].","year":"2014","key":"B57"},{"journal-title":"Treatment guidelines for Bipolar Disorders in The Netherlands.","year":"2015","key":"B58"},{"journal-title":"Farmacotherapeutisch Kompas.","year":"2020","key":"B59"},{"journal-title":"National Database for Drug Prices.","year":"2020","key":"B60"},{"journal-title":"Consumer Price Indices - The Netherlands.","year":"2022","key":"B61"},{"key":"B62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1017\/S0266462319000448","article-title":"Cost-effectiveness evaluations of psychological therapies for schizophrenia and bipolar disorder: a systematic review Europe PMC Funders Group.","volume":"35","author":"Shields","year":"2019","journal-title":"Int J Technol Assess Heal Care."},{"key":"B63","doi-asserted-by":"publisher","first-page":"432","DOI":"10.7326\/M17-1153","article-title":"A call for open-source cost-effectiveness analysis.","volume":"167","author":"Cohen","year":"2017","journal-title":"Ann Intern Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2165\/11593000-000000000-00000","article-title":"Addressing the challenge for well informed and consistent reimbursement decisions - the case for reference models.","volume":"29","author":"Haji","year":"2011","journal-title":"Pharmacoeconomics."},{"key":"B65","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/BMJ.39360.379664.BE","article-title":"Let cost effectiveness models be open to scrutiny.","volume":"335","author":"Poole","year":"2007","journal-title":"BMJ."},{"key":"B66","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40273-016-0479-8","article-title":"Benefits, challenges and potential strategies of open source health economic models.","volume":"35","author":"Dunlop","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"B67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/J.JVAL.2021.10.001","article-title":"Opportunities and barriers to the development and use of open source health economic models: a survey.","volume":"25","author":"Pouwels","year":"2022","journal-title":"Value Heal."},{"key":"B68","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0266462314000117","article-title":"Markov modeling and discrete event simulation in health care: a systematic comparison.","volume":"30","author":"Standfield","year":"2014","journal-title":"Int J Technol Assess Health Care."},{"key":"B69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/S40273-014-0147-9","article-title":"When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.","volume":"32","author":"Karnon","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"B70","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/J.1524-4733.2010.00768.X","article-title":"Functional impairment and disability across mood states in bipolar disorder.","volume":"13","author":"Rosa","year":"2010","journal-title":"Value Health."},{"key":"B71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/J.NEUBIOREV.2007.10.005","article-title":"Allostatic load in bipolar disorder: implications for pathophysiology and treatment.","volume":"32","author":"Kapczinski","year":"2008","journal-title":"Neurosci Biobehav Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1586\/ERN.09.31","article-title":"Clinical implications of a staging model for bipolar disorders.","volume":"9","author":"Kapczinski","year":"2014","journal-title":"Expert Rev Neurother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1586\/14737167.2016.1165608","article-title":"Advantages and disadvantages of discrete-event simulation for health economic analyses.","volume":"16","author":"Caro","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1017\/S0033291799002810","article-title":"Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness.","volume":"30","author":"Denicoff","year":"2000","journal-title":"Psychol Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/ARCHPSYC.1987.01800180050009","article-title":"The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.","volume":"44","author":"Keller","year":"1987","journal-title":"Arch Gen Psychiatry."},{"key":"B76","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1586\/14737167.2016.1141679","article-title":"Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices.","volume":"17","author":"Drost","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12992-016-0150-3","article-title":"The capabilities approach: fostering contexts for enhancing mental health and wellbeing across the globe.","volume":"12","author":"White","year":"2016","journal-title":"Global Health."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/J.1524-4733.2008.00389.X","article-title":"Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.","volume":"11","author":"Oostenbrink","year":"2008","journal-title":"Value Heal."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/S40273-019-00855-9","article-title":"Development and validation of the transparent uncertainty assessment (TRUST) tool for assessing uncertainties in health economic decision models.","volume":"38","author":"Grimm","year":"2020","journal-title":"Pharmacoeconomics."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1030989\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T15:14:46Z","timestamp":1701357286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1030989\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":79,"alternative-id":["10.3389\/fpsyt.2022.1030989"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1030989","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1030989"}}